{"id":8350,"date":"2025-06-23T16:21:17","date_gmt":"2025-06-23T08:21:17","guid":{"rendered":"https:\/\/regask.com\/?p=8350"},"modified":"2025-06-24T14:57:55","modified_gmt":"2025-06-24T06:57:55","slug":"ema-veroffentlicht-aktualisierte-prac-empfehlungen-zu-sicherheitssignalen-fur-zentral-und-national-zugelassene-arzneimittel","status":"publish","type":"post","link":"https:\/\/regask.com\/de\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\/","title":{"rendered":"EMA ver\u00f6ffentlicht PRAC-Sicherheitsupdates vom Juni 2025 f\u00fcr EU-Zulassungs\u2026"},"content":{"rendered":"<p data-start=\"375\" data-end=\"742\">Die Europ\u00e4ische Arzneimittel-Agentur (EMA) hat aktualisierte Sicherheitssignalempfehlungen ihres PRAC-Ausschusses ver\u00f6ffentlicht am <strong>2. Juni 2025<\/strong>.<br class=\"yoast-text-mark\" data-start=\"285\" data-end=\"288\" \/>Dieses Update spiegelt die anhaltenden Bem\u00fchungen der EMA wider, <strong>Verbesserung der Pharmakovigilanz\u00fcberwachung<\/strong> und st\u00e4rkt die \u00dcberwachung nach der Markteinf\u00fchrung zugelassener Arzneimittel in der gesamten Europ\u00e4ischen Union (EU).<\/p>\n<p data-start=\"744\" data-end=\"961\">Diese \u00fcberarbeiteten Richtlinien zielen darauf ab, die Aufsicht \u00fcber <strong>unerw\u00fcnschte Arzneimittelwirkungen (UAW)<\/strong>Sie tragen dazu bei, dass Marketing <strong>Zulassungsinhaber (MAHs)<\/strong> Bleiben Sie konform mit sich entwickelnden <strong>Arzneimittelsicherheitsvorschriften<\/strong>.<\/p>\n<h4 data-start=\"968\" data-end=\"1029\">\ud83d\udd0d Wichtige Highlights aus den PRAC-Empfehlungen vom Juni 2025<\/h4>\n<ul data-start=\"1031\" data-end=\"2657\">\n<li data-start=\"1031\" data-end=\"1316\">\n<p data-start=\"1033\" data-end=\"1316\"><strong>Aktualisierte Sicherheitssignale:<\/strong> Die Empfehlungen umfassen Aktualisierungen der Produktinformationen in mehreren <strong>Therapiegebiete<\/strong>, darunter Onkologie, Herz-Kreislauf-Behandlungen, Impfstoffe und andere Arzneimittel mit hoher Priorit\u00e4t. Diese stehen im Einklang mit den neuen Erkenntnissen zur Pharmakovigilanz in der gesamten EU.<\/p>\n<\/li>\n<li data-start=\"1318\" data-end=\"1688\">\n<p data-start=\"1320\" data-end=\"1370\"><strong>Zentral vs. national zugelassene Arzneimittel:<\/strong><\/p>\n<ul data-start=\"1373\" data-end=\"1688\">\n<li data-start=\"1373\" data-end=\"1522\">\n<p data-start=\"1375\" data-end=\"1522\">F\u00fcr <strong data-start=\"1379\" data-end=\"1413\">zentral zugelassene Arzneimittel<\/strong>, m\u00fcssen alle empfohlenen \u00c4nderungen von der <strong data-start=\"1464\" data-end=\"1521\">Ausschuss f\u00fcr Humanarzneimittel (CHMP)<\/strong>.<\/p>\n<\/li>\n<li data-start=\"1525\" data-end=\"1688\">\n<p data-start=\"1527\" data-end=\"1688\">F\u00fcr <strong data-start=\"1531\" data-end=\"1565\">national zugelassene Produkte<\/strong>Die Umsetzung f\u00e4llt unter die <strong data-start=\"1598\" data-end=\"1687\">Koordinierungsgruppe f\u00fcr gegenseitige Anerkennung und dezentrale Verfahren \u2013 Human (CMDh)<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<li data-start=\"1690\" data-end=\"1943\">\n<p data-start=\"1692\" data-end=\"1943\"><strong data-start=\"1692\" data-end=\"1726\">Erinnerung zur Einhaltung gesetzlicher Vorschriften<\/strong>: Zulassungsinhaber m\u00fcssen <strong data-start=\"1765\" data-end=\"1803\">regelm\u00e4\u00dfig PRAC-Ver\u00f6ffentlichungen \u00fcberpr\u00fcfen<\/strong> und aktualisieren Sie Produktkennzeichnungen, Packungsbeilagen oder andere Sicherheitsinformationen umgehend, um die neuesten Sicherheits\u00fcberwachungsprotokolle einzuhalten.<\/p>\n<\/li>\n<li data-start=\"1945\" data-end=\"2204\">\n<p data-start=\"1947\" data-end=\"2204\"><strong data-start=\"1947\" data-end=\"1976\">Sicherheitssignale kl\u00e4ren<\/strong>: Es ist wichtig zu beachten, dass die Identifizierung eines Sicherheitssignals keinen kausalen Zusammenhang zwischen einem Arzneimittel und einem unerw\u00fcnschten Ereignis best\u00e4tigt. Vielmehr weist es auf die Notwendigkeit einer weiteren wissenschaftlichen Bewertung oder von Vorsichtsma\u00dfnahmen hin.<\/p>\n<\/li>\n<li data-start=\"2206\" data-end=\"2414\">\n<p data-start=\"2208\" data-end=\"2414\"><strong data-start=\"2208\" data-end=\"2239\">Mehrsprachige Implementierung<\/strong>: Aktualisierte Produktinformationen werden in allen Amtssprachen der EU, einschlie\u00dflich Norwegisch und Isl\u00e4ndisch, zur Verf\u00fcgung gestellt, um eine harmonisierte Umsetzung in allen Mitgliedsstaaten zu unterst\u00fctzen.<\/p>\n<\/li>\n<li data-start=\"2416\" data-end=\"2657\">\n<p data-start=\"2418\" data-end=\"2657\"><strong data-start=\"2418\" data-end=\"2452\">Transparenz in der Pharmakovigilanz<\/strong>: A <strong data-start=\"2456\" data-end=\"2497\">kumulative Liste aller Sicherheitssignale<\/strong> vom PRAC gepr\u00fcft seit <strong data-start=\"2521\" data-end=\"2539\">September 2012<\/strong> bleibt \u00f6ffentlich zug\u00e4nglich und bietet Regulierungsbeh\u00f6rden und Interessenvertretern im Gesundheitswesen einen historischen Kontext und Einblick in Trends.<\/p>\n<\/li>\n<\/ul>\n<hr data-start=\"2659\" data-end=\"2662\" \/>\n<h4 data-start=\"2664\" data-end=\"2708\">\ud83c\udf10 Warum dies f\u00fcr Regulierungsteams wichtig ist<\/h4>\n<p data-start=\"2710\" data-end=\"2948\">Diese Updates spielen eine entscheidende Rolle bei der Erm\u00f6glichung <strong data-start=\"2757\" data-end=\"2808\">schnellere Umsetzung sicherheitsrelevanter \u00c4nderungen. <\/strong>Verbesserung <strong data-start=\"2820\" data-end=\"2847\">regulatorische Transparenz<\/strong>und unterst\u00fctzt <strong data-start=\"2864\" data-end=\"2892\">gleichberechtigter Patientenzugang<\/strong> auf die aktuellsten Daten zur Arzneimittelsicherheit in der gesamten EU.<\/p>\n<p data-start=\"2950\" data-end=\"3107\">F\u00fcr Regulierungsexperten, die <strong data-start=\"3034\" data-end=\"3056\">EU-Arzneimittelkonformit\u00e4t<\/strong>, <strong data-start=\"3058\" data-end=\"3078\">Aktualisierungen der Kennzeichnung<\/strong>, Und <strong data-start=\"3084\" data-end=\"3106\">Risikokommunikation<\/strong>.<\/p>\n<hr data-start=\"3109\" data-end=\"3112\" \/>\n<h4 data-start=\"3114\" data-end=\"3161\">\ud83d\udce5 M\u00f6chten Sie \u00fcber EU-Sicherheitsupdates auf dem Laufenden bleiben?<\/h4>\n<p data-start=\"3163\" data-end=\"3387\">Besuchen Sie die <a class=\"\" href=\"https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/pharmacovigilance-post-authorisation\/signal-management\/prac-recommendations-safety-signals\" target=\"_new\" rel=\"noopener\" data-start=\"3173\" data-end=\"3313\">offizielle Website<\/a> f\u00fcr die vollst\u00e4ndige Liste der Sicherheitssignal-Updates und produktspezifischen Anleitungen.<\/p>\n<p data-start=\"3389\" data-end=\"3534\">Oder erkunden Sie, wie <a href=\"https:\/\/regask.com\/de\/\">RegASK<\/a>Mithilfe der KI-gesteuerten Regulatory Intelligence-Plattform von k\u00f6nnen Sie globale \u00c4nderungen der Pharmakovigilanz in Echtzeit \u00fcberwachen.<\/p>","protected":false},"excerpt":{"rendered":"<p>Die Europ\u00e4ische Arzneimittel-Agentur (EMA) hat am 2. Juni 2025 aktualisierte Empfehlungen ihres PRAC-Ausschusses zu Sicherheitssignalen ver\u00f6ffentlicht. Diese Aktualisierung unterstreicht die kontinuierlichen Bem\u00fchungen der EMA, die Pharmakovigilanz zu verbessern und die \u00dcberwachung zugelassener Arzneimittel nach der Markteinf\u00fchrung in der gesamten Europ\u00e4ischen Union (EU) zu st\u00e4rken. Die \u00fcberarbeiteten Leitlinien zielen darauf ab, die \u00dcberwachung von unerw\u00fcnschten Arzneimittelwirkungen (UAW) zu verbessern. Sie tragen dazu bei\u2026<\/p>","protected":false},"author":43,"featured_media":8413,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[538,35],"tags":[225,227,496,497],"class_list":["post-8350","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-european-union","category-pharma-biotech-latest-insights","tag-drug-safety","tag-pharmacovigilance","tag-market-authorization-regs","tag-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.6 (Yoast SEO v27.6) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>EMA Releases June 2025 PRAC Safety Updates for EU-Authorized Medicines | RegASK<\/title>\n<meta name=\"description\" content=\"Discover the latest EMA PRAC safety updates for centrally and nationally authorized medicines, effective June 2025 across the EU.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/regask.com\/de\/ema-veroffentlicht-aktualisierte-prac-empfehlungen-zu-sicherheitssignalen-fur-zentral-und-national-zugelassene-arzneimittel\/\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"EMA Releases June 2025 PRAC Safety Updates for EU-Authorized Medicines\" \/>\n<meta property=\"og:description\" content=\"Discover the latest EMA PRAC safety updates for centrally and nationally authorized medicines, effective June 2025 across the EU.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/regask.com\/de\/ema-veroffentlicht-aktualisierte-prac-empfehlungen-zu-sicherheitssignalen-fur-zentral-und-national-zugelassene-arzneimittel\/\" \/>\n<meta property=\"og:site_name\" content=\"RegASK\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-23T08:21:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T06:57:55+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/regask.com\/wp-content\/uploads\/2025\/06\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines-12.png\" \/>\n\t<meta property=\"og:image:width\" content=\"800\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Reva Ananda\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:site\" content=\"@ASKRegASK\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reva Ananda\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2\u00a0Minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/regask.com\\\/zh\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/zh\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\\\/\"},\"author\":{\"name\":\"Reva Ananda\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\"},\"headline\":\"EMA Releases June 2025 PRAC Safety Updates for EU-Autho&hellip;\",\"datePublished\":\"2025-06-23T08:21:17+00:00\",\"dateModified\":\"2025-06-24T06:57:55+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/zh\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\\\/\"},\"wordCount\":381,\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/zh\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines-12.png\",\"keywords\":[\"Drug Safety\",\"Pharmacovigilance\",\"Market authorization regs\",\"Oncology\"],\"articleSection\":[\"European Union\",\"Pharma and Biotech\"],\"inLanguage\":\"de\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/regask.com\\\/zh\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\\\/\",\"url\":\"https:\\\/\\\/regask.com\\\/zh\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\\\/\",\"name\":\"EMA Releases June 2025 PRAC Safety Updates for EU-Authorized Medicines | RegASK\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/regask.com\\\/zh\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/regask.com\\\/zh\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines-12.png\",\"datePublished\":\"2025-06-23T08:21:17+00:00\",\"dateModified\":\"2025-06-24T06:57:55+00:00\",\"description\":\"Discover the latest EMA PRAC safety updates for centrally and nationally authorized medicines, effective June 2025 across the EU.\",\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/regask.com\\\/zh\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\\\/\\\/regask.com\\\/zh\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\\\/#primaryimage\",\"url\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines-12.png\",\"contentUrl\":\"https:\\\/\\\/regask.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines-12.png\",\"width\":800,\"height\":600,\"caption\":\"Ema Publishes Updated Prac Recommendations On Safety Signals For Centrally And Nationally Authorized Medicines 12\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/regask.com\\\/#website\",\"url\":\"https:\\\/\\\/regask.com\\\/\",\"name\":\"RegASK\",\"description\":\"The Regulatory AI Operating System for High-Performing Teams\",\"publisher\":{\"@id\":\"https:\\\/\\\/regask.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/regask.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/regask.com\\\/#\\\/schema\\\/person\\\/4023a3aab44f61a84d06ca8abfcbe926\",\"name\":\"Reva Ananda\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"EMA ver\u00f6ffentlicht PRAC-Sicherheitsupdates vom Juni 2025 f\u00fcr in der EU zugelassene Arzneimittel | RegASK","description":"Entdecken Sie die neuesten Sicherheitsupdates der EMA PRAC f\u00fcr zentral und national zugelassene Arzneimittel, g\u00fcltig ab Juni 2025 in der gesamten EU.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/regask.com\/de\/ema-veroffentlicht-aktualisierte-prac-empfehlungen-zu-sicherheitssignalen-fur-zentral-und-national-zugelassene-arzneimittel\/","og_locale":"de_DE","og_type":"article","og_title":"EMA Releases June 2025 PRAC Safety Updates for EU-Authorized Medicines","og_description":"Discover the latest EMA PRAC safety updates for centrally and nationally authorized medicines, effective June 2025 across the EU.","og_url":"https:\/\/regask.com\/de\/ema-veroffentlicht-aktualisierte-prac-empfehlungen-zu-sicherheitssignalen-fur-zentral-und-national-zugelassene-arzneimittel\/","og_site_name":"RegASK","article_publisher":"https:\/\/www.facebook.com\/RegASKRegulatoryAffairs\/","article_published_time":"2025-06-23T08:21:17+00:00","article_modified_time":"2025-06-24T06:57:55+00:00","og_image":[{"width":800,"height":600,"url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/06\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines-12.png","type":"image\/png"}],"author":"Reva Ananda","twitter_card":"summary_large_image","twitter_creator":"@ASKRegASK","twitter_site":"@ASKRegASK","twitter_misc":{"Written by":"Reva Ananda","Est. reading time":"2\u00a0Minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/regask.com\/zh\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\/#article","isPartOf":{"@id":"https:\/\/regask.com\/zh\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\/"},"author":{"name":"Reva Ananda","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926"},"headline":"EMA Releases June 2025 PRAC Safety Updates for EU-Autho&hellip;","datePublished":"2025-06-23T08:21:17+00:00","dateModified":"2025-06-24T06:57:55+00:00","mainEntityOfPage":{"@id":"https:\/\/regask.com\/zh\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\/"},"wordCount":381,"publisher":{"@id":"https:\/\/regask.com\/#organization"},"image":{"@id":"https:\/\/regask.com\/zh\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/06\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines-12.png","keywords":["Drug Safety","Pharmacovigilance","Market authorization regs","Oncology"],"articleSection":["European Union","Pharma and Biotech"],"inLanguage":"de"},{"@type":"WebPage","@id":"https:\/\/regask.com\/zh\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\/","url":"https:\/\/regask.com\/zh\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\/","name":"EMA ver\u00f6ffentlicht PRAC-Sicherheitsupdates vom Juni 2025 f\u00fcr in der EU zugelassene Arzneimittel | RegASK","isPartOf":{"@id":"https:\/\/regask.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regask.com\/zh\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\/#primaryimage"},"image":{"@id":"https:\/\/regask.com\/zh\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\/#primaryimage"},"thumbnailUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/06\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines-12.png","datePublished":"2025-06-23T08:21:17+00:00","dateModified":"2025-06-24T06:57:55+00:00","description":"Entdecken Sie die neuesten Sicherheitsupdates der EMA PRAC f\u00fcr zentral und national zugelassene Arzneimittel, g\u00fcltig ab Juni 2025 in der gesamten EU.","inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/regask.com\/zh\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\/"]}]},{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/regask.com\/zh\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines\/#primaryimage","url":"https:\/\/regask.com\/wp-content\/uploads\/2025\/06\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines-12.png","contentUrl":"https:\/\/regask.com\/wp-content\/uploads\/2025\/06\/ema-publishes-updated-prac-recommendations-on-safety-signals-for-centrally-and-nationally-authorized-medicines-12.png","width":800,"height":600,"caption":"Ema Publishes Updated Prac Recommendations On Safety Signals For Centrally And Nationally Authorized Medicines 12"},{"@type":"WebSite","@id":"https:\/\/regask.com\/#website","url":"https:\/\/regask.com\/","name":"RegASK","description":"Das regulatorische KI-Betriebssystem f\u00fcr leistungsstarke Teams","publisher":{"@id":"https:\/\/regask.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/regask.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/regask.com\/#\/schema\/person\/4023a3aab44f61a84d06ca8abfcbe926","name":"Reva Ananda"}]}},"_links":{"self":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/8350","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/users\/43"}],"replies":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/comments?post=8350"}],"version-history":[{"count":0,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/posts\/8350\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media\/8413"}],"wp:attachment":[{"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/media?parent=8350"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/categories?post=8350"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/regask.com\/de\/wp-json\/wp\/v2\/tags?post=8350"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}